Fischer Imaging's revenue is down as it prepares an FDA submission for its SenoScan full-field digital mammography system.Revenue decreased 3% to $13.7 for the first quarter of 2000 (end April 2) compared to $14.2 million for the first quarter of
Fischer Imaging's revenue is down as it prepares an FDA submission for its SenoScan full-field digital mammography system.Revenue decreased 3% to $13.7 for the first quarter of 2000 (end April 2) compared to $14.2 million for the first quarter of 1999. These figures do not include the sale of a $6.2 million technology license to GE Medical.
The deal with GE involves a Fischer design for a C-arm attachment for cardiology equipment. The license agreement says GE can manufacture the C-arm itself or outsource it to another company.
Fischer's net income for the first quarter of 2000 was $351,000 compared to a net loss of $2.4 million for the first quarter of 1999. These figures do not include income from the GE technology license sale.
Despite the 3% revenue decrease, Louis Rivelli, Fischer president and chief operating officer, said the company's net income for first quarter 2000 exceeded projections. He added that the quarter's operating expenses of $5.6 million were the lowest in five years.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.